Compare DexCom, Inc. (DXCM) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Rocket Lab USA Inc — how do they compare? DexCom, Inc. trades at $90.63 (market cap $33.79B), while Rocket Lab USA Inc trades at $80.96 (market cap $50.01B). The key difference: Rocket Lab USA Inc is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | RKLB | |
|---|---|---|
Market Cap | $33.79B | $50.01B |
Sector | Health | Technology |
52-Week High | $89.53 | $150.23 |
52-Week Low | $54.84 | $39.48 |
Enterprise Value | $33.24B | $47.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Rocket Lab (RKLB) trades at $81.17, up 1.41% today, showing strong momentum with a bullish technical outlook. The company reported record Q2 2026 revenue of $601.8M but missed EPS expectations, while maintaining a massive $2.36B backlog. Analysts remain overwhelmingly bullish with a $118 consensus target, though valuation metrics appear stretched with a P/S ratio of 60.8.
The stock offers significant upside potential driven by Neutron rocket development and growing space industry demand, but faces execution risks including margin pressures and cash burn. Near-term catalysts include the Neutron launch timeline and Iridium acquisition, though high valuation multiples require flawless execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
